RPT-Actavis deal for Allergan would be huge bet on branded drugs

Oct 8 (Reuters) - If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings.